65,437 trials
Irritable Bowel Syndrome With Diarrhea
Primary: Summary and Analysis of Overall Stool Consistency Response Rate - mITT Population — 42; 18; 33; 33 Participants — p=0.036
Suicide
Primary: Usability Satisfaction and Acceptability Questionnaire (USAQ) — 4.5 units on a scale
Retinopathy of Prematurity
Primary: Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24 — 80.0; 75.0; 66.2 Percentage of…
Acute Low Back Pain
Primary: Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire — 5; 4; 7 units on a scale
Acute Lymphocytic Leukemia · Acute Myeloid Leukemia · Non-Hodgkin Lymphoma
Primary: Percent of Participants That Successfully Used the iThermonitor — 100; 75; 63 % of participants
Atrial Fibrillation
Primary: Percentage of Patients With Freedom From Documented Symptomatic Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes — 80.7 Percentage of…
Type 2 Diabetes · Sleep Disordered Breathing
Primary: Non-REM Slow Wave Sleep — 47.3; 34.3; 57.3; 41.4 minutes
Anaplastic Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Complete Response Rate — 0 Participants
Diabetes Mellitus, Type 2 · Hypertension
Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks — 0.07; -0.71 percentage of glycated haemoglobin — p=0.0002
Atrial Fibrillation · Percutaneous Coronary Intervention
Primary: Time to First Adjudicated ISTH MBE or CRNMBE — 151; 154; 264; 196 Participants — p=<0.0001
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Post-Traumatic Headache
Primary: Number of Participants With Sustained Headache Relief — 12 Participants
Severe Acute Respiratory Illness
Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634
Neutropenia
Primary: Participants With Adverse Events (AEs) — 2; 28; 16; 2 Participants
Breast Cancer
Primary: Absolute Change in Mean Proliferative Rate Measured by Ki67% — -1.15; 4 percentage of Ki67 — p=0.32